RESUMO
The role of leukotrienes and prostaglandins in development of atopy has been prototypically established in studies of asthma pathogenesis. Likewise, both in vitro and in vivo studies of atopic dermatitis have demonstrated that these molecules maintain important pathophysiologic roles. Thus, it follows that targeted therapies against these molecules may be promising in management of atopic dermatitis. Montelukast has had questionable efficacy in patients with atopic dermatitis, whereas small pilots using zileuton did have some clinically significant improvement. There are several agents in development that target leukotrienes and/or prostaglandins as well, including OC000459, Q301, and ZPL-521. In atopic dermatitis, OC000459 did not demonstrate efficacy in clinical trials, and the efficacy of the other 2 agents remains to be seen. Should these medications prove promising, these topical agents may play a future role in chronic maintenance therapy and flare prophylaxis in atopic dermatitis, as antileukotriene therapy does in asthma.
Assuntos
Dermatite Atópica/tratamento farmacológico , Dermatite Atópica/imunologia , Antagonistas de Leucotrienos/uso terapêutico , Terapia de Alvo Molecular/métodos , Antagonistas de Prostaglandina/uso terapêutico , Acetatos/administração & dosagem , Adulto , Animais , Ciclopropanos , Dermatite Atópica/diagnóstico , Feminino , Previsões , Humanos , Hidroxiureia/administração & dosagem , Hidroxiureia/análogos & derivados , Masculino , Quinolinas/administração & dosagem , Índice de Gravidade de Doença , Sulfetos , Resultado do TratamentoAssuntos
Alérgenos/efeitos adversos , Dermatite Atópica/etiologia , Alérgenos/classificação , Alergia e Imunologia , Animais , Criança , Pré-Escolar , Dermatite Atópica/epidemiologia , Dermatologia , Alimentos/efeitos adversos , Hipersensibilidade Alimentar/epidemiologia , Hipersensibilidade Alimentar/etiologia , Departamentos Hospitalares , Hospitais Pediátricos , Humanos , Lactente , Ohio/epidemiologia , Hipersensibilidade a Amendoim/epidemiologia , Hipersensibilidade a Amendoim/etiologia , Pólen/efeitos adversos , Encaminhamento e Consulta , Estudos Retrospectivos , Testes Cutâneos , Centros de Atenção TerciáriaRESUMO
Hydroxyurea is a medication with many well-described cutaneous side effects, notably the dermatomyositis-like eruption known as hydroxyurea dermopathy. Although systemic lupus erythematosus has been reported with hydroxyurea use, cutaneous lupus has not. We report a novel case of chronic cutaneous lupus induced by hydroxyurea and propose that this is a side effect that is distinct from hydroxyurea dermopathy.
